CytomX Therapeutics (NASDAQ:CTMX) Price Target Raised to $15.00

CytomX Therapeutics (NASDAQ:CTMX) had its price objective raised by Guggenheim from $10.00 to $15.00 in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other research analysts have also recently weighed in on the stock. Barclays raised their price objective on shares of CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 4th. Piper Sandler upped their target price on CytomX Therapeutics from $6.50 to $10.00 and gave the company an “overweight” rating in a research note on Tuesday, January 20th. Cantor Fitzgerald increased their target price on CytomX Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a report on Wednesday, February 4th. JPMorgan Chase & Co. raised CytomX Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $7.00 to $12.00 in a research report on Monday, March 16th. Finally, HC Wainwright boosted their price target on CytomX Therapeutics from $10.00 to $17.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CytomX Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $13.22.

CytomX Therapeutics Price Performance

CytomX Therapeutics stock opened at $4.45 on Wednesday. The stock’s 50 day moving average price is $5.28 and its 200 day moving average price is $4.12. CytomX Therapeutics has a 1-year low of $0.40 and a 1-year high of $8.21. The company has a market cap of $757.35 million, a PE ratio of -111.25 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Monday, March 16th. The biotechnology company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14). The company had revenue of $0.66 million for the quarter, compared to analyst estimates of $7.33 million. CytomX Therapeutics had a negative return on equity of 19.77% and a negative net margin of 22.79%. On average, equities research analysts anticipate that CytomX Therapeutics will post -0.05 EPS for the current fiscal year.

Insider Transactions at CytomX Therapeutics

In other news, SVP Marcia Belvin sold 31,492 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $6.42, for a total value of $202,178.64. Following the sale, the senior vice president owned 300,760 shares of the company’s stock, valued at approximately $1,930,879.20. The trade was a 9.48% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Sean A. Mccarthy sold 118,969 shares of the company’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $6.42, for a total transaction of $763,780.98. Following the completion of the sale, the chief executive officer directly owned 1,078,922 shares of the company’s stock, valued at $6,926,679.24. The trade was a 9.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 191,063 shares of company stock worth $1,226,624 over the last 90 days. 6.60% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On CytomX Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. acquired a new stake in shares of CytomX Therapeutics in the first quarter worth $39,000. Woodline Partners LP acquired a new position in CytomX Therapeutics during the first quarter valued at $1,054,000. Geode Capital Management LLC raised its position in CytomX Therapeutics by 103.4% during the second quarter. Geode Capital Management LLC now owns 1,745,176 shares of the biotechnology company’s stock valued at $3,963,000 after buying an additional 887,218 shares during the period. Franklin Resources Inc. purchased a new stake in CytomX Therapeutics in the 2nd quarter worth about $13,096,000. Finally, XTX Topco Ltd acquired a new stake in CytomX Therapeutics during the 2nd quarter worth about $277,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

Key Headlines Impacting CytomX Therapeutics

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Multiple high‑profile analyst upgrades and big price‑target increases (Jefferies, Barclays, Guggenheim, Wedbush and others) have pushed positive momentum and attracted buyers. Jefferies raises price target to $16
• Positive Sentiment: Trading volume spiked after the analyst upgrade cycle, suggesting the upgrades translated into real buying interest rather than just headlines. Strong trading volume after upgrades
• Neutral Sentiment: CytomX priced an equity offering to raise about $234 million, which materially extends runway and funding for the pipeline but will dilute existing shareholders. Timing and use of proceeds will determine the net effect. Equity offering announcement
• Neutral Sentiment: Short‑interest reports in recent filings show effectively zero reported short interest (data appears inconsistent/NaN), so short positioning is not clearly driving moves at this time. Short interest data (reporting)
• Negative Sentiment: CytomX missed Q1/quarterly estimates on both EPS and revenue, a concrete near‑term negative that increases uncertainty around execution and near‑term cash generation. Shares down on disappointing earnings
• Negative Sentiment: An analyst cut the Q1 EPS forecast, adding to concerns about near‑term financial performance and guidance. Q1 EPS forecast decreased
• Negative Sentiment: Clustered insider selling on March 17 (CEO Sean McCarthy, CFO Christopher Ogden, SVP Marcia Belvin and others) — sizable block sales by multiple senior executives — is dampening sentiment even if some sales are routine. Insider sales report
• Negative Sentiment: Some sell‑side and independent commentary warn that early clinical data may not yet justify elevated valuations, which could pressure momentum traders and cap further upside until clearer clinical/corporate catalysts arrive. Valuation caution commentary

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.